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ABSTRACT
  
Angiotensin converting enzyme (ACE) inhibitor drug intermediates, ECPPA
(S)-ethoxycarbonyl-3-phenylpropyl) L-alanine) ,ECPPL(N2-(1(S) ethoxycarbonyl-3 
Phenyl propyl)-  N6 trifloro acetyl L-lysine)have been synthesized by using the 
enzyme Lipase. Angiotensin converting enzyme inhibitor drug intermediates are 
synthesized stereo selectively by using Novo SP 435 supplied by Novozymes.  Choral 
specificity for the ACE inhibitor drug intermediates is (SS). The formed desired (SS) 
isomer is matched by the standard sample with HPLC method.
KEYWORDS
Angiotensin converting enzyme (ACE) inhibitor drug intermediates, ECPPA (N2
(1(S)-ethoxycarbonyl-3-phenylpropyl) L-alanine) and ECPPL (N2-(1(S)-
ethoxycarbonyl-3 Phenyl propyl) - N6 trifloro acetyl L-lysine)
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INTRODUCTION
              Enzymes are remarkable molecular devices that determine the pattern of 
chemical transformations in organic synthesis. The most striking characteristics of 
enzymes are their catalytic power and stereo specificity. Enzymes are highly effective 
in catalyzing diverse chemical reactions because of their ability to specifically bind to 
a substrate and their ability to accelerate reactions by several orders of magnitude. 
Applying enzymes or organisms in organic synthesis has become one of the fastest 
growing techniques for the development of new methodology and the work in this 
area has been comprehensively growing every year1-3. Lipase has been utilized by 
many scientists for highly stereo specific syntheses of chiral compounds.4
Angiotensin-converting enzyme inhibitors 5(ACE inhibitors) are a new class of potent 
specific inhibitors which generate the powerful vasoconstrictor angiotensin. 
Angiotensin-converting enzymes6 (peptidol dipeptide hydrolase. EC 3.4.15-1) 
generates the powerful vasoconstrictor substance angiotensin II by removing the C-
terminal dipeptide from the precursor decapeptide angiotensin.I) 7. The enzyme also 
inactivates the vasodilating substance bradykinin8   Angiotensin-converting enzyme 
(ACE) inhibition is an effective therapy for the control of hypertension and congestive 
heart failure. Angiotensin Converting Enzyme (ACE) Inhibitors are used to manage 
hypertension (high blood pressure9-10. These medications lower blood pressure by 
preventing the formation of angiotensin II, a hormone in the body that causes blood 
vessels to constrict (close).11 This constriction of the blood vessels is due to 
angiotensin II, a hormone that is an important component of hypertension. Blocking 
the hormone causes the blood vessels to relax or dilate (open), and thus helps to 
reduce blood pressure.12
        Angiotensin-converting enzyme inhibitor (ACE inhibitors) drugs are Benazepril 
13 Lotensin14Captopril15 (Capoten), Enalapril (Vasotec), Enalaprilat 16 Injection 
(Vasotec IV) Fosinopril 17 Lisinopril 18 Prinivil, Zestril, Moexipril19 Univasc, 
Perindopril20 Aceon, Quinapril Cupric, Ramipril 21 Altace, Trandolapril 22.   Enalapril, 
Ramipril, Trandalapril, Quinopril and Lisinopril have been synthesized. Syntheses of 
Enalapril, Quinapril, Ramipril and Trandolapril require Common building block 
Intermediate like N2 (S) Ethoxy carbonyl phenyl propyl alanine (ECPPA). Syntheses 
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of Lisinopril require the intermediate N2 – ((S)-1 ethoxy carbonyl-3-phenyl propyl)-
trifloroacetyl L-lysine (ECPPL).
           Various synthetic methods are reported for the preparation of ECPPA and 
ECPPL 23.  A favorable diastereoselective synthesis of - (1-S-ethoxycarbonyl-3-
phenylpropyl)-S-alanine is carried out by Michael addition of S-alanine benzyl ester
to ethyl-4-oxo-4-phenyl-2-butenoate in a region and diastereo selective fashion and 
subsequent catalytic hydrogenolysis.
             In the preparation of ECPPA, the carboxylic acid group of alanine is first 
protected by benzyl group and condensed with acryl ate in presence of mild base like 
TEA giving ECPPA 24.  ECPPL is prepared from Ph CO CHCH CO2Et  when reacted 
with CF3 CONH (CH2) 4 CH (NH2) COOH in presence of an alkali metal salt to form a 
Michael addition product followed by the addition of not less than one equivalent of 
mineral acid and after completion of hydrogenation, the desired product is obtained. 
Acid addition is to prevent conversion of SS isomers to RS isomer 25. Another process 
for the preparation of ECPPL is the condensation of  phenyl propionaldehyde with 
N6 trifloro acetyl L- Lysine in presence of NaCN, which after hydrolysis gives the SS 
isomer. After purification it gives 99% of chiral purity product 26.
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Fig I: STRUCTURES OF ECPPA AND ECPPL
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EXPERIMENTAL PROCEDURE
               All chemicals used were of commercial grade. Here we describe a stereo 
selective synthesis of the generally usable component for the ACE inhibitors i.e.N2-
(s)-1-ethoxy carboxyl-3-phenyl propyl)-L-alanine and further application of N2 –(s)-1-
ethoxy carboxyl-3-phenyl propyl)-N6 tri floro acetyl L-lysine. (Fig I)The reaction of 
trans beta Benzoyl Acryl ate with different amino acids L-alanine or tri floro acetyl L-
Lysine in presence of Novo SP 435 led to the corresponding Michael addition 
product. The products produced from the enzymatic condensation are analyzed by 
HPLC method .In order to quantify their concentration and reaction rate HPLC 
method is quite useful. HPLC conditions are useful for the reaction monitoring and 
standard sample retention time comparisons. (Table1).We have conducted various 
experiments with different solvents like Diisopropyl ether, Diethyl ether, Tert-butyl 
alcohol, 1,4 Dioxane, Toluene, Benzene, N-Hexane, Acetonitrile, Ethyl acetate
and the substrate and enzyme ratio has been used as 100:1(Table 2& Table 3).
           Reaction was conducted below room temperature and the products formed 
were confirmed by HPLC reaction monitoring. The samples were collected from 
reaction bottle and are acidified with mineral acid and then they are analyzed. We 
observed that minimum time for the optimum conversion of reactants into products is 
6 to 7 hours. If the reaction is kept longer than 7 hrs some side products have been 
formed. These are mainly formed from the-Benzoyl acryl ate. The positive aspect of 
the synthesis of ECPPA and ECPPL is with enzymatic reaction.  The highlight of the 
reaction is the formation of desired (S, S) configuration of ECPPA and ECPPL and 
there were no unwanted (R.S) configuration products. When L-lysine derivative is 
condensed with -Benzoyl acryl ate in presence of LiOH, it forms both SS: RS 
configuration products in the ratio of 70:30.  Novo SP 435 enzyme is highly specific 
in its biocatalysis in the synthesis of ACE inhibitor intermediates. It catalyses the 
reaction in such a way that it avoids the formation of unwanted (R, S) isomers and 
forms the desired drug product of (S, S) isomer and the difficulties in the separation 
of the desired isomer are avoided. It is a much easier synthetic preparation than the 
conventional organic synthesis. It is an advantageous synthesis over the conventional 
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synthesis. The method can be considered as a biotechnological synthesis. It adds to 
the protection of the environment and can be classified under green chemistry 
experiment.Percent of Michael addition product formed with Novo SP 435 in various 
organic solvents are given as under. (Table 2 & 3)
TYPICAL EXPERIMENTAL PROCEDURE
            A round bottom flask is taken. It is fitted with a magnetic stirrer. Novo SP 435 
enzyme and required amount of the solvent (10 volumes of the solvent) were added. 
-Benzoyl acryl ate and L- Alanine are taken in equal molar ratios at 25 oC .The 
reaction mass is maintained for 5 to 6 hours and the samples were analyzed as per the 
procedure shown in the above HPLC methods (Table-1). The samples were analyzed 
regularly for every one hour .All the samples were compared with standard samples 
prepared from the standard procedures. The reactions were run for two to three times 
and the reproducibility of the reaction was checked. (Scheme I). The reaction was 
conducted with various solvents as shown in table-2.In the preparation of 
                ECPPL -Benzoyl acryl ate and Tri floro acetyl L-lysine were taken in the 
ratio of 1:1 at 25oC in a round bottom flask fitted with a magnetic stirrer. Novo SP 
435 enzyme was taken in the flask and it was dissolved in ten volumes of the solvent. 
The reaction mixture was stirred for 7 to 8 hrs. (Scheme II). The samples were 
analyzed as per the HPLC methods shown in table-1. The samples were analyzed 
regularly for every hr. The samples were compared with the standard samples .The 
reproducibility of the reaction was checked number of times by repeating the 
experiment. The reaction was conducted with various solvents and the results were 
shown in table-3.
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METHODS AND MATERIALS
             Analytical data were obtained with a Thermo Finnigan Flash EA 1112 
analyzer. 1H NMR spectra were obtained at 300 MHz using a Brucker 300 Avance 
NMR spectrometer running X-WIN NMR software. The chemical shifts are relative 
to tetramethylsilane (TMS). All chemicals and solvents were reagent grade and were 
used as purchased without further purification. Melting points were determined using 
an Electro-thermal 9100 melting-point apparatus. FT-IR spectra were recorded as KBr 
pellets on a Jasco FT/IR-600 Plus spectrometer. 1H (400 MHz) and 13C (100 MHz) 
NMR spectra were recorded at ambient temperature in CDCl3. Chemical shifts (d) are 
expressed in units of parts per million relative to TMS.
RESULTS AND DISCUSSION
            Stereo selective enzymatic synthesis of ACE inhibitor drug intermediateN2
(1(S)-ethoxycarbonyl-3-phenylpropyl) L-alanine) ECPPA, (N2- (1(S)-
ethoxycarbonyl-3 Phenyl propyl) - N6 trifloro acetyl L-lysine) ECPPL has been 
carried out. Vicente Gotor 27 has reported the mechanism of Lipase biocatalysed 
Michael addition of secondary amines to acrylonitrile using Novozyme 435. 
Enzymatic desymetrization of the homo allylic diol with Novo SP 435 allowed optical 
pro(s) selectivity to provide the desired (-) (s) monoacetate. The predominant Enantio 
pure monoester produced by ammonolysis of di ethyl 3 hydroxy glutarate catalyzed 
by immobilized lipase B from (Novozyme 435) was ethyl (3S)-4-carbamoyl- 3 
hydroxy butanoate. In the present strategy, the synthesis of ACE inhibitor drug 
intermediate likes ECPPA and ECPPL were carried out by Novo SP 435 supplied by 
Novozymes. In this synthetic procedure, the required chiral specificity for the above 
intermediates is SS and the chiral purity of the product was observed to be high 
(>99%).
          Here we reported an unprecedented NOV SP 435 catalyzed condensation of -
benzyl acryl ate with amino acid derivatives. Different amino acid derivatives with 
benzoyl acryl ate was prepared during the preparation of ACE inhibitor drug
intermediates. The catalytic effect of the enzyme was demonstrated by the 
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combination of different experiments. These experiments demonstrated that state of 
the art enzymatic transformation has reached an extraordinary level making them 
valuable and innovative methods for use in the chemical and pharmaceutical industry.
The synthesized desired (SS) isomer has been matched by the standard sample with 
known HPLC methods. Details of HPLC column are given in table 1. The analytical 
data of the products is given in table 4.
Table-1
S.NO. CONDITIONS ECPPA ECPPL
1 Column Finepaksil C18-5 Finepaksil C18-5
2 Column Temperature 400 c 400 c
3 Flow Rate 1.5 ml/Minute 1 ml/Minute
4 Detector UV 210nm UV 210nm
5 Eluent 60mM phosphate 
Buffer (ph 2.5)/acetonitrile 
85/15
60mM phosphate 
buffer (ph 2.5)/
Acetonitrile 85/15
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Table -2: Michael addition reaction of ECPPA with different solvents.
S.No
.
Subatrate-1 Subatrate-2 Solvent Michael 
addition 
product 
Name
% Of Michael 
addition product 
formed by HPLC
1. -Benzoyl 
acryl ate
L-Alanine Diisopropyl 
ether
ECPPA 78
2. -Benzoyl 
acryl ate
L-Alanine Diethyl 
ether
ECPPA 68
3. -Benzyl 
acryl ate
L-Alanine Tert-butyl 
alcohol
ECPPA 65
4. -Benzoyl 
acryl ate
L-Alanine 1,4 
Dioxane
ECPPA 63
5. -Benzoyl 
acryl ate
L-Alanine Toluene ECPPA 60
6. -Benzoyl 
acryl ate
L-Alanine Benzene ECPPA 55
7. -Benzoyl 
acryl ate
L-Alanine N-Hexane ECPPA 52
8. -Benzoyl 
acryl ate
L-Alanine Acetonitrile ECPPA 48
9. -Benzoyl 
acryl ate
L-Alanine Ethyl 
acetate
ECPPA 29
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Table-3: Michael addition reaction of ECPPL with different solvents.
S.No. Subatrate-
1
Subatrate-2 Solvent Michael 
addition 
product 
name
% Of Michael 
addition 
product formed 
by HPLC
1. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
Diisopropyl 
ether
ECPPL 76
2. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
Diethyl 
ether
ECPPL 68
3. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
Tert-butyl 
alcohol
ECPPL 65
4. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
1,4 Dioxane ECPPL 61
5. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
Toluene ECPPL 58
6. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
Benzene ECPPL 55
7. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
n-Hexane ECPPL 53
8. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
Acetonitrile ECPPL 40
9. -Benzoyl 
acryl ate
Tri floro acetyl 
L-lysine
Ethyl 
acetate
ECPPL 22
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IR spectral data of ECPPA
           IR spectrum of ECPPA is recorded in KBr (Pellets).  The FT IR spectrum 
shows characteristic peaks at 3400-3600 cm-1 region, which is characteristic
frequency of νOH of L alanine.  A stretching frequency observed at 1735 cm-1 is 
due to ν C=O frequency of ester group.  A ν C=O at 1710 cm-1 is due to carboxylic 
acid group. A ν CH stretching vibration observed at 2850 cm-1 is due to CH3 and 
CH2 groups. The νOH bending vibration is observed at 1400 cm-1.  The νNH 
stretching vibration observed at 3300 cm-1 is a weak absorption.  An absorption 
band observed at760 cm-1 is interpreted to the wagging band of νNH .
1H NMR Spectral Data of ECPPA
            The 1HNMR spectrum of ECPPA was recorded in CDCl3   using TMS as 
the standard.  The spectrum shows its characteristic signals accounting for the 
proposed structure of the compound.  A signal at δ 1.23 is due to CH3 (a) (s, 3H, 
CH3 (a)). A signal at δ 1.30 is due to the CH3 of C2H5 (s, 3H, CH3 (b)) of COOEt. 
A signal at δ 2.09 is due to CH2 (s, 2H, of CH2). Another signal at δ 2.55 is due to 
(s, 2H, CH2 adjacent to phenyl ring). A signal at δ 3.45 is due to the tertiary carbon 
attached to NH group(s, 1H, CH of NH group). A signal at δ 3.67 is due to another 
tertiary carbon attached to COOH group (s, 1H, CH of COOH group). A signal 
observed at δ 4.12 is due to CH2 of C2H5 (s, 2H, CH2 of C2H5). A cluster of signals 
observed in the region of 7.08-7.21 are due to aromatic protons .A signal at δ 11.00 
is due to hydroxyl proton (s.1H, OH).
13C NMR Spectral Data of ECPPA
            The 13C NMR spectrum of ECPPA was recorded in CDCl3 using TMS as 
standard.  A signal at δ 14.1 is due to C of CH3 of C2H5 of COOEt group. A signal 
of δ 17.4 is due CH3 of L –alanine moiety. A signal at δ 32.9 is due to C of CH2
group. A signal at 30.6 is due to C of CH2 attached to phenyl group. A signal at δ 
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57.6 is due to asymmetric carbon of L alanine moiety. A signal at δ 58.2 is due to 
asymmetric carbon of phenyl propyl group. A signal at δ 61.3 is due to C of CH2
group of COOEt group. Signals at δ 126.1, 128.2 and 128.9 are due to aromatic 
carbons of phenyl group. A signal at δ138.1 is due to the tertiary aromatic carbon 
of phenyl group attached to propyl group. A signal at 171.6 is due to carbonyl 
carbon of COOEt group. A signal at δ 174.9 is due to the carbonyl carbon of 
carboxylic acid group.
IR Spectral Data of ECPPL
          IR spectrum of ECPPL was recorded in KBr (Pellets). The FT IR spectrum 
shows its Characteristic peaks at 3200-3600 cm-1 is due to the characteristic νOH. 
A stretching frequency observed at 1725 cm-1 is due to ν C=O frequency of ester 
group. A ν C=O at 1706 cm-1 is due to νC=O of carboxylic acid group. The νC=O 
of CF3 -C=O is observed at 1680 cm
-1. A ν CH stretching vibration observed at 
2850 –2950 cm-1 is due to CH3 and CH2 groups.  The νOH bending vibration is 
observed at 1420 cm-1. The stretching vibration observed at 3250 -3300 cm-1 as a 
weak absorption is due to νNH.  The νNH wagging absorption band is observed at 
760 -780 cm-1 28.
1H NMR spectrum of ECPPL
            The 1H NMR spectrum of ECPPL is recorded in CDCl3 using TMS as 
standard (δ) (ppm). A signal at δ 1.3 is due to CH3 group (s, 3H, CH3); Signals 
from 1.2 to 2.5 are due various CH2 protons. These signals account for seven 
different CH2 groups present in the molecule. A signal at δ 2.01 is due to the CH 
proton of the asymmetric carbon present on the phenyl propyl group.  A signal at δ 
3.49 is due to the asymmetric CH group of alanine moiety. Signals at 7.08, 7.12 
and 7.21 are due to the aromatic protons on the phenyl group. A signal at δ 8.0 is 
due to the NH proton.  A signal at δ 11.0 is due to the hydroxyl proton of 
carboxylic acid group.29
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13C NMR spectrum of ECPPL
               A 13C NMR spectrum of ECPPL was recorded in CDCl3 using TMS as 
standard. The 13CNMR spectrum shows its characteristic NMR signals correlating 
very well with the expected structure of the molecule.  A signal at δ 14.1 is due to 
methyl carbon of COOC2H5 group.  Signals at δ 21.4, 29.6, 29.8, 31.2, and 33.4 are 
due to Carbons of CH2 group. A signal at δ 40.1 is due to the methylene carbon 
attached to the NH group. A signal at δ 61.0 is due to the methylene carbon 
attached to the asymmetric carbon of phenyl propyl group.  Signals at 63.9 and 
58.7 are due the asymmetric carbons. A cluster of signals at 126.1, 128.2 and 128.9 
are due to the aromatic carbons of phenyl group. A signal at δ 138.1 is due to the 
tertiary carbon of the phenyl group attached the propyl group. A signal at δ 116.3 
is due to the carbon of CF3 group. A signal at δ 157.4 is due to the carbonyl carbon 
attached to the trifloro methyl group. A signal at δ 170.3 is due to the carbonyl 
carbon of the COOEt group. A signal at δ 174.9 is due to the carbonyl group of 
carboxylic acid group of amino acid moiety.
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Table 4: Analytical Data of the compounds
Name Formula Found(Calcd)
Carbon            Hydrogen         Nitrogen
( R) –2-((S) – 4-
Oxo-4-
phenylburan-2-
ylamino)propionic
acid(Pro drug)
C15H19NO5 61.50
(61.42)
6.60
(6.53)
4.85
(4.78)
ECPPA
C15H21NO4 65.00
(64.50)
7.71
(7.58)
4.88
(5.01)
(R)-2-((S)-4-oxo-4-
phenyl-butan-2yl-
amino)-6-(2, 2, 2)-
trifloro acetamido)
hexanoic acid(Pro 
drug)
C20H25F3N2O6 54.10
(53.81)
5.71
( 5.64)
6.50
(6.28)
ECPPL C20H27F3N2O5 56.10
(55.50)
6.41
(6.29)
6.53
(6.42)
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